Jane Street’s Kymera Therapeutics KYMR Stock Holding History

Jane Street’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$550K	Buy	+4,800	New	+$412K	﹤0.01%	7782
2026 Q1	–	Sell	-10,200	Closed	-$794K	–	12342
2025 Q4	$794K	Buy	10,200 +4,300	+73%	+$290K	﹤0.01%	6635
2025 Q3	$334K	Sell	5,900 -19,300	-77%	-$870K	﹤0.01%	8694
2025 Q2	$1.1M	Buy	+25,200	New	+$868K	﹤0.01%	5439
2025 Q1	–	Sell	-5,900	Closed	-$237K	–	10085
2024 Q4	$237K	Sell	5,900 -11,800	-67%	-$533K	﹤0.01%	8124
2024 Q3	$838K	Buy	17,700 +9,000	+103%	+$397K	﹤0.01%	6227
2024 Q2	$260K	Hold	8,700	–	–	﹤0.01%	8014
2024 Q1	$350K	Hold	8,700	–	–	﹤0.01%	7312
2023 Q4	$222K	Buy	+8,700	New	+$156K	﹤0.01%	8060
2023 Q2	–	Sell	-58,700	Closed	-$1.74M	–	9178
2023 Q1	$1.74M	Buy	58,700 +7,300	+14%	+$235K	﹤0.01%	4058
2022 Q4	$1.28M	Sell	51,400 -1,000	-2%	-$26.7K	﹤0.01%	4585
2022 Q3	$1.14M	Buy	+52,400	New	+$1.38M	﹤0.01%	5176
2022 Q2	–	Sell	-26,800	Closed	-$1.13M	–	10342
2022 Q1	$1.13M	Buy	+26,800	New	+$1.13M	﹤0.01%	5877

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jane Street's KYMR Position: Q2 2026 in Review

Jane Street increased its Kymera Therapeutics (KYMR) stake by 0.61% in Q2 2026, buying an estimated $1.55K and bringing the position to 2,957 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #8936.

Jane Street first reported a position in KYMR in Q4 2020 and has held it in 18 quarters since. The position peaked at $4.99M in Q4 2023. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Jane Street held 2,957 shares of Kymera Therapeutics worth $339K as of Q2 2026.
Jane Street bought 18 Kymera Therapeutics shares in Q2 2026, an estimated $1.55K.
Kymera Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8936 holding.
Jane Street first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 18 quarters since.
Jane Street's Kymera Therapeutics position peaked at $4.99M in Q4 2023.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.